The DIM BioConvS Innovation Day 2024, taking place on November 28th at the Regional Council of Île-de-France in Saint-Ouen-sur-Seine, represents a crucial event for the future of synthetic biology and biotherapy. Organized by the DIM BioConvS (Domaine d’Intérêt Majeur Bioconvergence pour la santé), this event aims to foster interdisciplinary collaboration, bringing together researchers, companies, and innovation platforms to explore the latest advancements and opportunities in these dynamic fields.

The Innovation Day focuses on bridging the gap between synthetic biology and biotherapies, particularly those targeting the microbiome. This year’s event will showcase how innovations in synthetic biology can drive the next generation of therapeutic solutions. Attendees will have the opportunity to engage in short talks, innovation pitches, and a poster session that will highlight cutting-edge research and technologies. The event is designed to promote direct interactions between academia and industry, enabling researchers and businesses to connect and explore potential partnerships.

One of the key highlights of the day will be the “village of stands,” which will feature local companies and research platforms, providing a comprehensive view of the Île-de-France region’s scientific innovations. Participants will have the chance to engage with these exhibitors, learn about their latest developments, and explore potential collaborations. Whether attending the short talks or visiting the stands, participants can expect a day rich in information and networking.

The Paris Biofoundry’s involvement in this event underscores its ongoing commitment to advancing the field of synthetic biology and supporting the development of biotherapeutic solutions. By participating in such collaborative platforms, the biofoundry continues to play a critical role in driving the adoption of biofoundry technologies, which streamline the process of bioproduction and enhance the scalability of therapeutic applications.

At the Innovation Day, the Paris Biofoundry will contribute to discussions on how biofoundries facilitate cross-disciplinary collaboration between synthetic biologists, biotechnologists, and clinicians. As biofoundries become increasingly vital for advancing therapeutic research and industrial applications, the Biofoundry’s participation in events like this serves as a testament to its role in advancing the biotechnology ecosystem, offering invaluable insights into the development and deployment of biotechnological innovations.

This day of innovation and collaboration is an opportunity to engage with leaders in synthetic biology and biotherapies, share ideas, and form lasting partnerships. The event’s focus on microbiome-centered biotherapies and synthetic biology innovations is particularly relevant, as the microbiome is increasingly recognized for its critical role in human health. By showcasing innovations in both research and application, DIM BioConvS Innovation Day 2024 is set to be a key event in shaping the future of biotechnological research and therapeutics.

L’article Paris Biofoundry at DIM BioConvS Innovation Day 2024 est apparu en premier sur Paris Biofoundry.

The SynBioTherapy Symposium 2024, happening today November 27th, is held at the Learning Planet Institute in Paris. This event, organized by DIM BioConvS, serves as a pivotal gathering at the intersection of synthetic biology and biotherapies, exploring the transformative potential of these fields to address critical healthcare challenges.

As part of the event, Stéphane Lemaire, Director of the Paris Biofoundry, will take the stage to highlight the crucial role of biofoundries in advancing therapeutic research. His talk will delve into the innovative capabilities of biofoundries, particularly their ability to accelerate the design, testing, and production of biotherapeutic solutions. Through a combination of automation, data-driven design, and cutting-edge experimental tools, biofoundries like the Paris Biofoundry empower researchers to overcome the traditional limitations of biotech development.

This symposium will bring together prominent international experts to share insights into the latest breakthroughs in the application of synthetic biology to therapeutics. Notable speakers such as Velia Siciliano, Head of Synthetic Biology and Systems for Biomedicine at IIT Naples, and Filippo Menolascina, Director of the Engineering Biology Centre at the University of Edinburgh, will present on topics ranging from gene therapy to the engineering of mammalian cells for therapeutic use. These discussions will highlight the intersection of biotechnological advancements and real-world clinical applications, with a focus on microbiome-centered biotherapies, an emerging field with great promise for treating a range of diseases.

The event will also provide attendees with ample opportunities for networking and collaboration. Interactive sessions, roundtable discussions, and opportunities to connect with researchers from around the world will enable participants to explore the synergies between synthetic biology, biotherapy, and the broader healthcare industry.

The Paris Biofoundry, as an active player in synthetic biology, continues to foster innovation and facilitate collaboration across international research communities. Its participation in such events underlines its commitment to addressing global health challenges and advancing biotechnological solutions. By leveraging the latest advancements in automation, data science, and experimental technologies, biofoundries are poised to redefine the future of healthcare and therapeutic development.

As synthetic biology and biotherapy continue to evolve, the SynBioTherapy Symposium 2024 provides an invaluable platform for researchers, biotechnologists, and medical professionals to stay at the forefront of these dynamic fields. The event promises to be a significant milestone in driving the next wave of biotechnological innovation, ensuring that both synthetic biology and biotherapies can be applied to solve some of the world’s most pressing health issues.

L’article The Paris Biofoundry at the SynBioTherapy Symposium 2024 est apparu en premier sur Paris Biofoundry.